Key points are not available for this paper at this time.
Confounding appearance of radiographic changes in recurrent high grade glioma (HGG) patients treated with multimodality immunotherapy presents a challenge to the neuro-radiologist. A clinical need exists to improve upon conventional criteria for assessment of GBM on standard-of-care (SOC; T1w, T2w, FLAIR, and T1w-enhanced) MRI to help distinguish treatment-related effects from true disease progression. We have investigated the feasibility of intensity-based segmentation of tumor tissue types on multiparametric MRI (mpMRI) to inform response assessment in HGG patients treated with bevacizumab, hypofractionated stereotactic radiotherapy, and pembrolizumab.
Ravi et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: